

1 Estimating the generation time for 2 influenza transmission using 3 household data in the United States

4 Louis Yat Hin Chan¹, Sinead E. Morris^{1,9}, Melissa S. Stockwell², Natalie M. Bowman³, Edwin Asturias⁴,
5 Suchitra Rao⁴, Karen Lutrick⁵, Katherine D. Ellingson⁵, Huong Q. Nguyen⁶, Yvonne Maldonado⁷, Son H.
6 McLaren², Ellen Sano², Jessica E. Biddle¹, Sarah E. Smith-Jeffcoat¹, Matthew Biggerstaff¹, Melissa A.
7 Rolfes¹, H. Keipp Talbot⁸, Carlos G. Grijalva⁸, Rebecca K. Borchering¹, Alexandra M. Mellis¹, RVTN-
8 Sentinel Study Group

- 9 1. Centers for Disease Control and Prevention
- 10 2. Columbia University Irving Medical Center
- 11 3. University of North Carolina at Chapel Hill
- 12 4. University of Colorado School of Medicine and Children's Hospital Colorado
- 13 5. University of Arizona
- 14 6. Marshfield Clinic Research Institute
- 15 7. Stanford University
- 16 8. Vanderbilt University Medical Center
- 17 9. Goldbelt Professional Services

18 * Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30329,
19 US (LouisChan@cdc.gov)

20 Keywords

- 21 • Generation interval
- 22 • Serial interval
- 23 • Incubation period
- 24 • Pre-symptomatic transmission
- 25 • Household transmission
- 26 • Respiratory diseases

27 Abstract

28 The generation time, representing the interval between infections in primary and secondary cases, is
29 essential for understanding and predicting the transmission dynamics of seasonal influenza, including
30 the real-time effective reproduction number (R_t). However, comprehensive generation time estimates
31 for seasonal influenza, especially post the 2009 influenza pandemic, are lacking.

32 We estimated the generation time utilizing data from a 7-site case-ascertained household study in the
33 United States over two influenza seasons, 2021/2022 and 2022/2023. More than 200 individuals who
34 tested positive for influenza and their household contacts were enrolled within 7 days of the first illness
35 in the household. All participants were prospectively followed for 10 days completing daily symptom
36 diaries and collecting nasal swabs, which were tested for influenza via RT-PCR. We analyzed these data

37 by modifying a previously published Bayesian data augmentation approach that imputes infection times
38 of cases to obtain both intrinsic (assuming no susceptible depletion) and realized (observed within
39 household) generation times. We assessed the robustness of the generation time estimate by varying
40 the incubation period, and generated estimates of the proportion of transmission before symptomatic
41 onset, infectious period, and latent period.

42 We estimated a mean intrinsic generation time of 3.2 (95% credible interval, CrI: 2.9-3.6) days, with a
43 realized household generation time of 2.8 (95% CrI: 2.7-3.0) days. The generation time exhibited limited
44 sensitivity to incubation period variation. Estimates of the proportion of transmission that occurred
45 before symptom onset, the infectious period, and the latent period were sensitive to variation in
46 incubation periods.

47 Our study contributes to the ongoing efforts to refine estimates of the generation time for influenza.
48 Our estimates, derived from recent data following the COVID-19 pandemic, are consistent with previous
49 pre-pandemic estimates, and will be incorporated into real-time R_t estimation efforts.

50 Introduction

51 The generation time, a crucial parameter in understanding the dynamics of infectious diseases, is
52 defined as the time interval between infections in primary and secondary cases. In the context of
53 seasonal influenza, estimation of the generation time becomes increasingly important for predicting the
54 trajectory of outbreaks and informed public health decision-making during an influenza season. This
55 interval represents the time between typical influenza infections, reflecting when most transmission is
56 likely to happen.

57 Estimating the generation time is challenging because few investigations can accurately detect the exact
58 time of infection. The generation time is often inferred from the serial interval, defined as the time
59 between symptom onsets of primary and secondary cases (Svensson 2007), due to the practicality of
60 observing symptom onsets rather than infections. However, this alternative measure may not always
61 approximate the generation time due to its dependence on the incubation period, defined as the
62 duration from infection to symptom onset, and the possibility of asymptomatic infections.

63 Accurate estimation of the generation time is important for predicting the real-time effective
64 reproduction number (R_t), a metric used to describe transmission intensities through time (Gostic, et al.
65 2020). During the 2023/2024 influenza season, the Centers for Disease Control and Prevention (CDC)
66 estimated the current epidemic growth status for influenza infections in the U.S. as either growing or
67 declining based on the R_t (Centers for Disease Control and Prevention 2024) (Centers for Disease
68 Control and Prevention 2024). For this estimate, the generation time was approximated with a serial
69 interval from a study by Cowling et al. (Cowling, et al. 2009) that utilized data collected in Hong Kong in
70 2007, prior to the 2009 H1N1 influenza pandemic.

71 To improve our understanding of seasonal influenza outbreaks, there is a need for more contemporary
72 generation time estimates, especially following the COVID-19 pandemic. This analysis provides updated
73 generation time estimates derived from an influenza household transmission study (Rolfes, et al. 2023)
74 conducted during the 2021/2022 and 2022/2023 influenza seasons in the U.S. We employ a model using
75 a published Bayesian data augmentation approach (Hart, Abbott, et al. 2022) (Hart, Maini and
76 Thompson 2021) (Hart, Miller, et al. 2022) to impute missing event times, including infections and

77 symptom onsets of cases, and estimate generation times. We estimate both the intrinsic generation
78 time, which assumes no susceptible depletion, as well as the realized household generation time
79 observed within the household setting. We also estimate the serial interval. We derived estimates
80 across the two seasons, virus types (influenza A and B), and household sizes to understand potential
81 differences and robustness to model assumptions. The insights gained from these sensitivity analyses
82 contribute to our understanding of the reliability of our estimates across different data stratifications
83 and assumptions, providing evidence that the generation time has remained substantially unchanged
84 over the last decade or two.

85 We also estimate other transmission parameters, including the proportion of transmission before
86 symptomatic onset, the infectious period, and the latent period. This helps in assessing pre- and post-
87 symptomatic transmission, thereby providing insights to inform effective disease control strategies.
88 These insights are crucial for preventing pre-symptomatic transmission through interventions such as
89 isolation.

90 **Material and methods**

91 **Household data**

92 Participants included in this analysis were enrolled in a 7-site case-ascertained household study, the
93 Respiratory Virus Transmission Network – Sentinel (RVTN-S), conducted in the U.S. over two consecutive
94 influenza seasons: 2021/2022 and 2022/2023 (Rolfes, et al. 2023). After informed consent was obtained,
95 the study enrolled individuals identified with influenza infections via polymerase chain reaction (PCR)
96 testing and their household contacts within 7 days of the initial illness onset within the household.
97 Households were only enrolled if the index case who first presented for clinical testing was the first
98 symptomatic or positive person in the household, with no other members of the household
99 symptomatic on the first day of index case symptoms. Participants, including both index cases and
100 household contacts, were then prospectively followed for 10 days, during which they completed daily
101 symptom diaries and collected daily nasal swabs, which were tested for influenza via RT-PCR.

102 The dataset encompasses detailed information regarding symptoms and viral testing, including four
103 main variables used in the model: whether individuals tested positive for influenza, their symptomatic
104 status, dates of positive test results, and dates of symptom onset. Using the test positivity and
105 symptomatic status, we stratified individuals into three types: symptomatic infected, asymptomatic
106 infected, and uninfected. Both the dates of positive test results and symptom onset were used as upper
107 bounds for the date of infection for each individual.

108 In the primary analysis, we excluded households with multiple co-primary cases, i.e., more than one
109 individual exhibiting the same date of the earliest symptom onset concurrently. To assess robustness,
110 we also performed a separate stratified analysis that included households both with and without
111 multiple co-primary cases.

112 **Estimating the generation time**

113 We employed a Susceptible-Exposed-Infectious-Recovered (SEIR) model with Bayesian data
114 augmentation, originally developed by Hart et al. (Hart, Maini and Thompson 2021) for analyzing COVID-
115 19 contact tracing data. The model was also used in two subsequent studies of household data in the
116 United Kingdom (Hart, Abbott, et al. 2022) (Hart, Miller, et al. 2022). The SEIR model, referred to as the
117 mechanistic model, which includes compartments for asymptomatic, pre-symptomatic and symptomatic

118 infectious stages (Hart, Maini and Thompson 2021). Each stage may have different relative
119 infectiousness, or transmission rates. Upon infection and entry into the non-infectious exposed stage,
120 individuals may progress to become infectious through one of two pathways: either by remaining
121 asymptomatic or by developing symptoms following a pre-symptomatic stage. Consequently,
122 transmissions may occur before symptom onset, depending on the length of the incubation period.

123 We estimated both intrinsic and realized generation times by integrating data augmentation Markov
124 Chain Monte Carlo (MCMC) techniques (Hart, Abbott, et al. 2022), to impute infection times and
125 symptom onset of cases. The intrinsic generation time assumes no depletion of susceptible individuals,
126 providing an estimate of the time it takes for an infected individual to infect others in the community
127 with an unlimited supply of susceptible individuals. The realized household generation time reflects the
128 actual time interval observed within households, restricted by the depletion of susceptible individuals
129 over time. Susceptible depletion refers to the gradual reduction in the number of individuals within a
130 population that have not yet been infected with a virus. For example, within the SEIR framework,
131 members may become infected, develop immunity, and subsequently be removed from the susceptible
132 pool. Considering this distinction allows for a more thorough understanding of influenza transmission
133 dynamics, capturing both theoretical and observed aspects of transmission.

134 We also estimated several other crucial transmission parameters, including the proportion of
135 transmission before symptomatic onset, the ratio of pre-symptomatic to symptomatic transmission
136 rates (i.e., relative infectiousness of symptomatic infected individuals before symptom onset compared
137 to after), as well as the latent period, the pre-symptomatic infectious period, and the symptomatic
138 infectious period, all under the SEIR framework.

139 In adapting the model for our influenza study, we used estimates for the incubation period of influenza
140 A from a systematic review by Lessler et al. (Lessler, et al. 2009). In sensitivity analyses, we explored
141 variations derived from parallel estimates for influenza B (Lessler, et al. 2009) and for influenza
142 A(H1N1)pdm09 (Tuite, et al. 2010).

143 Regarding the relative infectiousness of asymptomatic infected individuals compared with symptomatic
144 infected individuals, we assumed a value of 0.57 (i.e., asymptomatic infected individuals were 43% less
145 infectious than those symptomatic infected) based on the mean estimate from a recent study (Tsang, et
146 al. 2023), and we also conducted sensitivity analyses using values of 0.11 and 1.54 based on the
147 corresponding 95% credible interval (CrI).

148 To compare posterior distributions of estimates, we calculated the overlapping index, a measure of
149 distribution similarities (Pastore 2018) (Pastore and Calcagni 2019). A value close to 1 indicates high
150 similarity, implying no substantial differences, while a value close to 0 indicates low similarity, implying
151 substantial differences. We compared the estimates of generation time across multiple data
152 stratifications and sensitivity analyses to the primary results excluding households with multiple co-
153 primary cases.

154 The model was implemented in R (version 4.3.1) with 1,000,000 Markov chain Monte Carlo iterations,
155 discarding the initial 20% as burn-in and obtaining posterior distributions by thinning every 100
156 iterations. The code for the model is available at [https://github.com/CDCgov/influenza-
157 generation-time-us](https://github.com/CDCgov/influenza-generation-time-us).

158 **Ethics statement**

159 This study was reviewed and approved by the IRB at Vanderbilt University Medical Center (see 45 C.F.R.
160 part 46.114; 21 C.F.R. part 56.114).

161 **Results**

162 **The household data**

163 During the data cleaning process, we excluded 93 individuals who did not have at least two valid PCR
164 tests and 2 individuals who were the only household members. In the primary analysis, we further
165 excluded 23 individuals from 6 households that had co-primary cases. The final cleaned dataset,
166 covering both seasons, comprised 820 individuals from 246 households (Table 1).

167 As shown in Table 1, more households were enrolled in the 2022/2023 season. In both seasons,
168 influenza A viruses predominantly circulated. In the 2021/2022 season, influenza A(H3N2) virus was
169 identified in 78% of individuals, and influenza A(H1N1) virus was identified in 1% of individuals. In the
170 2022/2023 season, the percentages changed to 64% and 6%, respectively. Since households consisting
171 of 3 or 4 members were the majority, we stratified the data into two groups: those with 2 or 3
172 members, and those with 4 or greater, to ensure comparability in quantity.

Data stratifications	Number of individuals (households)	Symptomatic infected %	Asymptomatic infected %	Uninfected %
All data excluding households with multiple co-primary cases (primary analysis)	820 (246)	59.4% (487/820)	7.2% (59/820)	33.4% (274/820)
Season 2021/2022	308 (90)	59.4% (183/308)	7.5% (23/308)	33.1% (102/308)
Season 2022/2023	512 (156)	59.4% (304/512)	7.0% (36/512)	33.6% (172/512)
Influenza A	683 (209)	61.1% (417/683)	7.5% (51/683)	31.5% (215/683)
Influenza B	137 (37)	51.1% (70/137)	5.8% (8/137)	43.1% (59/137)
Household size of 2 or 3	393 (152)	62.6% (246/393)	5.3% (21/393)	32.1% (126/393)
Household size of 4 or greater	427 (94)	56.4% (241/427)	8.9% (38/427)	34.7% (148/427)
All data including households with multiple co-primary cases	843 (252)	60.3% (508/843)	7.0% (59/843)	32.7% (276/843)

173 *Table 1. Characteristics of household data.*


174 **Consistent estimates of the generation time across data stratifications and**
175 **parameter assumptions**

176 In the primary analysis using all data excluding households with multiple co-primary cases from both
177 seasons, we estimated a mean intrinsic generation time of 3.2 (95% credible interval, CrI: 2.9-3.6) days
178 (Figure 1A, 1B and Table 2). The corresponding mean (intrinsic) serial interval was 3.2 (95% CrI: 2.8-3.5)
179 days, with a standard deviation (SD) of 2.2 (95% CrI: 1.8-2.6) days. The mean realized household
180 generation time was 2.8 (95% CrI: 2.7-3.0) days, nearly half a day shorter than the mean intrinsic
181 generation time.

182 We found no substantial differences in the mean intrinsic generation time estimates across multiple
183 data stratifications (Figure 1C and Supplemental Table S1). The overlapping indices for both 2021/2022
184 and 2022/2023 were high at 71% and 87%, respectively, aligning with the primary analysis above.
185 Influenza A data showed a notable high overlapping index of 94%, reflecting its dominance, as influenza
186 A was identified in 83% of the individuals. Conversely, using the data exclusively from influenza B yielded
187 a similar mean but with a wider credible interval due to the smaller sample size, i.e., influenza B was
188 identified in only 17% of the individuals, resulting in a lower overlapping index of 47%. Upon examining
189 household sizes, although we found slightly longer mean intrinsic and realized household generation
190 times in smaller households compared to larger ones, the overlapping index for household sizes of 2 or 3
191 members and 4 or more members were moderately high at 61% and 74%, respectively. Incorporating
192 households with co-primary cases remained consistent with a moderately high overlapping index of
193 64%, indicating the similarity between exclusion and inclusion of multiple co-primary cases.

194 The mean intrinsic generation time exhibited limited sensitivity to variations in the incubation period
195 (Figure 1D and Supplemental Table S2). In the primary analysis shown above, we used an incubation
196 period with a mean of 1.55 days and a standard deviation (SD) of 0.66 days by fitting previously
197 published estimates (Lessler, et al. 2009) to a gamma distribution (Supplemental Figure S1). When
198 considering a shorter incubation period, which yielded a mean of 0.61 days and a SD of 0.25 days
199 (Lessler, et al. 2009), the mean intrinsic generation time remained unchanged with an overlapping index
200 of 86%. Conversely, with a longer incubation period, which yielded a mean of 4.30 days and a SD of 1.25
201 days (Tuite, et al. 2010), the mean intrinsic generation time increased slightly with an intermediate
202 overlapping index of 56%.

203 Our estimates were not sensitive to changes in the relative infectiousness of asymptomatic infected
204 individuals, due to the limited number of asymptomatic infected individuals in this study (Supplemental
205 Figure S6). We found no substantial differences in the mean intrinsic generation time estimates
206 (Supplemental Table S2), as indicated by overlapping indices of 94% and 97% when using the values of
207 0.11 and 1.54 compared to the primary value of 0.57 (Tsang, et al. 2023).



208

209 *Figure 1. (A) Distributions of intrinsic generation time and serial interval using the posterior samples. The lines represent the*
 210 *median, and the shaded areas denote the 95% credible intervals (CrI). The blue color represents the intrinsic generation time*
 211 *distribution, while the orange color represents the serial interval distribution. (B) Posterior distribution of mean intrinsic and*
 212 *realized household generation time. (C) Posterior distributions of mean intrinsic generation time across seasons, virus types,*
 213 *household sizes, and with multiple co-primary cases. The incubation period, derived from influenza A, had a mean of 1.55 days*
 214 *and a standard deviation (SD) of 0.66 days (Lessler, et al. 2009). Only for influenza B, we assumed the shorter incubation period*
 215 *to yield a mean of 0.61 days and a standard deviation (SD) of 0.25 days (Lessler, et al. 2009). (D) Posterior distributions of mean*
 216 *intrinsic generation time estimated using the full dataset across different incubation periods.*

	Mean	SD
Intrinsic generation time (days)	3.2 (2.9-3.6)	2.1 (1.8-2.5)
Realized household generation time (days)	2.8 (2.7-3.0)	1.6 (1.5-1.8)
Serial interval (days)	3.2 (2.8-3.5)	2.2 (1.8-2.6)

217 *Table 2. Posterior mean (95% CrIs) of estimates in primary analysis using the full dataset. The incubation period, derived from*
 218 *influenza A, had a mean of 1.55 days and a standard deviation (SD) of 0.66 days (Lessler, et al. 2009). The relative infectiousness*
 219 *of asymptomatic infected individuals compared with symptomatic infected individuals was assumed to be 0.57 (Tsang, et al.*
 220 *2023).*

221 Sensitivity of other transmission parameters to the incubation period

222 In our sensitivity analyses, where we varied the assumed incubation period from the mean of 1.55 days
 223 and SD of 0.66 days, we found significant influences on several crucial pre-symptomatic transmission
 224 parameters and the duration of various symptomatic infectious stages (Table 3 and Supplemental Figure
 225 S5).

226 Notably, given the shorter incubation period (mean of 0.61 days and SD of 0.25 days), the proportion of
 227 transmission before symptomatic onset was lower at 3% (95% CrI: 0-6%), and the ratio of pre-
 228 symptomatic to symptomatic transmission rates indicated a lower relative infectiousness of
 229 symptomatic infected individuals before symptom onset compared to after. This indicates that the
 230 majority of transmission occurred after individuals developed symptoms. Consequently, this was

231 reflected in a shorter latent period of 0.4 (95% CrI: 0.2-0.6) days and pre-symptomatic infectious period
 232 of 0.2 (95% CrI: 0.0-0.4) days, or a longer symptomatic infectious period of 2.6 (95% CrI: 2.3-3.0) days.

233 Conversely, given the longer incubation period (mean of 4.30 days and SD of 1.25 days), the proportion
 234 of transmission before symptomatic onset was higher at 76% (95% CrI: 65-87%), and the ratio of pre-
 235 symptomatic to symptomatic transmission rates was higher. This resulted in a longer latent period of 0.9
 236 (95% CrI: 0.2-1.6) days and pre-symptomatic infectious period of 3.4 (95% CrI: 2.7-4.1) days, while the
 237 symptomatic infectious period was shorter at 1.2 (95% CrI: 0.7-1.9) days.

Incubation period	Shorter	Primary	Longer
Mean intrinsic generation time (days)	3.2 (2.8-3.6)	3.2 (2.9-3.6)	3.4 (3.1-3.7)
Proportion of transmission before symptomatic onset	0.03 (0.00-0.06)	0.16 (0.07-0.25)	0.76 (0.65-0.87)
Ratio of pre-symptomatic and symptomatic transmission rates	0.6 (0.1-1.7)	0.7 (0.2-1.9)	1.3 (0.5-3.2)
Latent period (days)	0.4 (0.2-0.6)	0.9 (0.2-1.4)	0.9 (0.2-1.6)
Pre-symptomatic infectious period (days)	0.2 (0.0-0.4)	0.7 (0.2-1.3)	3.4 (2.7-4.1)
Symptomatic infectious period (days)	2.6 (2.3-3.0)	2.0 (1.7-2.4)	1.2 (0.7-1.9)

238 *Table 3. Posterior mean (95% CrIs) of estimates of generation time and transmission parameters given different assumed*
 239 *incubation periods. The primary incubation period, derived from influenza A, had a mean of 1.55 days and a standard deviation*
 240 *(SD) of 0.66 days (Lessler, et al. 2009). The shorter incubation period, derived from influenza B, yielded a mean of 0.61 days with*
 241 *a SD of 0.25 days (Lessler, et al. 2009), while the longer incubation period, derived from influenza A(H1N1)pdm09, had a mean*
 242 *of 4.30 days with a SD of 1.25 day (Tuite, et al. 2010). The relative infectiousness of asymptomatic infected individuals compared*
 243 *with symptomatic infected individuals was assumed to be 0.57 (Tsang, et al. 2023).*

244 Discussion

245 Estimates of generation time

246 This study employed a Bayesian data augmentation approach (Hart, Maini and Thompson 2021, Hart,
 247 Abbott, et al. 2022, Hart, Miller, et al. 2022) to estimate both intrinsic and realized generation times
 248 using data collected from a U.S. household study during the post COVID-19 pandemic influenza seasons,
 249 2021/2022 and 2022/2023. Our findings indicate that the intrinsic generation time, reflecting
 250 transmission dynamics within community settings, ranged from 2.9 to 3.6 days, while the realized
 251 household generation time, restricted to household settings, ranged from 2.7 to 3.0 days. These
 252 estimates of the generation time for influenza fall within the uncertainty bounds of pre-pandemic
 253 studies, including directly using viral shedding data (Carrat, et al. 2008) and other contact tracing data
 254 (Fraser, et al. 2009) (te Beest, et al. 2013) (Lau, et al. 2015), with estimates varying between 2 and 4
 255 days, suggesting that there has not been substantial change since the 2009 H1N1 influenza pandemic.
 256 Additionally, the overlapping indices higher than 70% suggested no substantial differences between the
 257 two influenza seasons.

258 Both seasons of this study were atypical, being the first seasons since the COVID-19 pandemic, during
 259 which the immunity to influenza had potentially decreased. The 2022/2023 season, in particular,
 260 experienced an early influenza activity peak along with RSV and COVID-19 outbreaks. Despite these
 261 unusual circumstances, both seasons dominated by influenza A(H3N2) were tested in our sensitivity

262 analyses, which were based on different parameter assumptions. The generation time estimates
263 remained similar to those from earlier studies, suggesting that virus transmission dynamics within
264 households have not changed substantially and may not vary widely between types. However, further
265 work is needed to fully explore estimates for influenza that were less prevalent in this study (i.e.,
266 influenza B and A(H1N1)).

267 Our finding that the realized household generation time was shorter than the intrinsic generation time
268 could be attributed to the depletion of susceptible individuals over time. As household members
269 become infected and develop immunity, although individuals may still be infectious, there are no
270 susceptible contacts still exposed to each case. This depletion terminates transmission chains,
271 diminishing the potential for further infections. This process, along with factors such as closer proximity
272 and longer exposure times inherent to household settings, can increase the chance of transmission
273 within households, leading to a shorter observed generation time.

274 Our updated estimates, particularly for the intrinsic generation time, may be useful for ongoing
275 modeling efforts which require estimated generation times, such as real-time influenza R_t estimation
276 (Centers for Disease Control and Prevention 2024) (Centers for Disease Control and Prevention 2024)
277 (Gostic, et al. 2020). Our estimates are slightly shorter than the serial interval estimated by Cowling et
278 al. (Cowling, et al. 2009) at 3.6 days (95% confidence interval, CI: 2.9-4.3). This shorter interval suggests
279 a more rapid spread, potentially leading to higher estimated R_t and emphasizes the need for prompt
280 and effective interventions to control transmission.

281 Reliability of other transmission parameters

282 Comparing our other parameter estimates with prior research, we found the mean serial interval to be
283 3.2 days, within the 95% CI of 2.9 to 4.3 days reported by Cowling et al. (Cowling, et al. 2009). Our
284 estimate also falls within the 3-to-4-day range of uncertainty reported in previous household studies
285 (Cauchemez, Donnelly, et al. 2009, Petrie, et al. 2013, Levy, et al. 2013, Xu, et al. 2015, Cowling, et al.
286 2010, Suess, et al. 2012, Boëlle, et al. 2011, Tsang, et al. 2016).

287 We estimated a latent period of less than a day, which is shorter than the 1 to 3 days reported in other
288 studies (Tuite, et al. 2010) (Cori, et al. 2012). It is possible that this shorter latent period could be
289 influenced by undocumented exposures outside households. For instance, both the index case and
290 infected household member may have been exposed to influenza elsewhere, with the index case
291 developing symptoms before the household member. Consequently, when the household member
292 becomes sick, we attribute it to the index case within the household, but this infection could have
293 originated from previous exposure outside the household, which has not been accounted for in this
294 analysis. Nonetheless, we excluded households with multiple co-primary cases to reduce these effects,
295 ensuring accurate assessment of transmission dynamics within each household.

296 Furthermore, there was substantial uncertainty in our estimates for the symptomatic infectious period,
297 which ranged from 1 to 3 days, given different assumed incubation periods. Likewise, there has been a
298 wide range of estimates in earlier studies, including those less than a day (Cori, et al. 2012) and more
299 than 3 days (Tuite, et al. 2010) (Cauchemez, Carrat, et al. 2004).

300 The estimates of the pre-symptomatic transmission parameters and the duration of various
301 symptomatic stages should be interpreted with caution due to the inherent uncertainty in accurately
302 estimating the incubation period. Our estimates incorporated values from various studies based on

303 different types or subtypes of influenza (Lessler, et al. 2009) (Tuite, et al. 2010). This variability in the
304 incubation period contributes to a wide range of pre-symptomatic transmission parameters. Without a
305 reliable input for the incubation period, accurately determining these transmission dynamics becomes
306 challenging.

307 **Implications for preventing transmission**

308 Understanding the proportion of transmission that occurs prior to symptoms is critical to informing
309 effective disease control strategies and assessing the potential impact of post-symptomatic mitigation
310 measures, such as isolation of cases. We estimated that between 3% and 76% of transmission may occur
311 before a person develops symptoms. This wide range was influenced by our assumptions of the
312 incubation period, which were taken from a variety of previously published estimates. Longer incubation
313 period assumptions yielded higher estimates of the percentage of transmission that occurred before
314 symptoms. Similarly, attempts to estimate individual-level pre-symptomatic transmission using viral
315 kinetics data have revealed substantial heterogeneity (Morris, et al. 2024). This highlights that pre-
316 symptomatic transmission of influenza does occur, aligning with findings for other respiratory pathogens
317 like SARS-CoV-2 (Buitrago-Garcia, et al. 2022).

318 Given the wide range of pre-symptomatic transmission, relying solely on isolation of symptomatic
319 individuals may reduce but not eliminate influenza transmission. Although isolation measures initiated
320 after symptom onset are likely to mitigate at least some influenza spread, given the relatively low levels
321 of asymptomatic infection and pre-symptomatic transmission among the majority of individuals, there
322 remains large heterogeneity (Morris, et al. 2024). A layered approach, including isolation of ill or
323 infected people, maintaining good respiratory hygiene, and promoting influenza vaccination, may be
324 most effective to reduce transmission within households (Centers for Disease Control and Prevention
325 2024). This underscores the importance of vaccination as the primary recommendation to prevent
326 influenza-associated morbidity and mortality, especially for individuals at increased risk of influenza
327 complications.

328 **Modeling details and limitations**

329 While our reliance on household data might introduce limitations, such as the presence of multiple co-
330 primary cases, sensitivity analyses confirmed the robustness of our generation time estimates to various
331 data stratifications and model assumptions. Nevertheless, there are several limitations to our study.

332 First, we did not account for vaccination status. This omission is less likely to impact our estimates for
333 influenza given similarities in viral load dynamics between infected vaccinated and unvaccinated
334 individuals (Morris, et al. 2024) (Suess, et al. 2012). Nevertheless, it is possible that different vaccination
335 statuses could be associated with different generation time estimates.

336 Second, we did not account for potential exposures outside households. When we excluded household
337 members who did not have at least two valid PCR tests, the household sizes were reduced in our
338 analysis. While this might not directly affect our generation time estimates, it could lead to an
339 overestimation of overall infectiousness due to the absence of unobserved uninfected members.

340 Third, it is essential to acknowledge the influence of the COVID-19 pandemic on our influenza data.
341 Generalizing these findings to pre-pandemic or post-pandemic periods should be done with caution.
342 During the period when this study was conducted, individuals may have been more likely to adopt
343 preventive measures against transmission within the home, such as self-isolating, practicing good

344 respiratory and hand hygiene, wearing masks, and reducing contact with household members. These
345 non-pharmaceutical interventions, alongside changes in human behavior and heightened awareness of
346 infection control, could have impacted the spread of influenza.

347 Conclusions

348 Through comprehensive data collected during the 2021/2022 and 2022/2023 influenza seasons in the
349 U.S., we provide updated estimates of the generation time, essential for informing influenza modeling
350 and public health strategies. Despite the significant changes in public behavior and preventive measures
351 due to the COVID-19 pandemic, our study did not detect substantial changes in the generation time of
352 influenza since the 2009 influenza pandemic. This finding is particularly significant given that the study
353 period followed the extreme measures implemented to prevent COVID-19, which also reduced the
354 transmission of influenza and other respiratory infections. Our findings contribute to our understanding
355 of influenza transmission dynamics within households and underscore the importance of ongoing
356 research for effective outbreak management.

357

358 Author contributions

	1	2	3	4	5	6	7	8	9	10	11	12	13	14
LYHC	Y	-	Y	-	Y	Y	-	-	Y	-	Y	Y	Y	Y
SEM	-	-	-	-	Y	Y	-	-	-	-	-	-	-	Y
MSS	-	Y	-	-	-	-	-	-	-	-	-	-	-	Y
NMB	-	Y	-	-	Y	-	-	-	-	-	-	-	-	Y
EA	-	Y	-	-	-	-	-	-	-	-	-	-	-	Y
SR	-	Y	-	-	-	-	-	-	-	-	-	-	-	Y
KL	-	Y	-	-	-	-	-	-	-	-	-	-	-	Y
KDE	-	Y	-	-	-	-	-	-	-	-	-	-	-	Y
HQN	-	Y	-	-	-	-	-	-	-	-	-	-	-	Y
YM	-	Y	-	-	-	-	-	-	-	-	-	-	-	Y
SHM	-	Y	-	-	-	-	-	-	-	-	-	-	-	Y
ES	-	Y	-	-	-	-	-	-	-	-	-	-	-	Y
JEB	-	Y	-	-	-	-	-	-	-	-	-	-	-	Y
SESJ	-	Y	-	-	-	-	-	-	-	-	-	-	-	Y
MB	-	-	-	-	-	-	-	-	-	Y	-	-	-	Y
MAR	-	Y	-	-	-	-	-	-	-	-	-	-	-	Y
HKT	-	Y	-	Y	-	-	-	-	-	-	-	-	-	Y
CGG	-	Y	-	Y	-	-	-	-	-	-	-	-	-	Y
RKB	Y	-	Y	-	Y	Y	-	-	-	Y	-	-	-	Y
AMM	Y	Y	Y	-	Y	Y	Y	Y	-	Y	-	-	Y	Y

359 ... choose from the following items: <https://credit.niso.org/>

360 <https://www.elsevier.com/researcher/author/policies-and-guidelines/credit-author-statement>

- 361 1. Conceptualization
- 362 2. Data curation
- 363 3. Formal analysis
- 364 4. Funding acquisition
- 365 5. Investigation
- 366 6. Methodology
- 367 7. Project administration
- 368 8. Resources
- 369 9. Software
- 370 10. Supervision
- 371 11. Validation
- 372 12. Visualization
- 373 13. Roles/Writing - original draft
- 374 14. Writing - review & editing.

375 Acknowledgments

- 376 • The authors thank the following members of the Respiratory Virus Transmission Network –
- 377 Sentinel (RVTN-S) study teams:
- 378 a. Vanderbilt University Medical Center: Chris Lindsell, Judy King, John Meghreblian,
- 379 Samuel Massion, Brittany Creasman, Lauren Milner, Andrea Stafford Hintz, Jorge

- 380 Celedonio, Ryan Dalforno, Maria Catalina Padilla-Azain, Daniel Chandler, Paige Yates,
381 Brianna Schibley-Laird, Alexis Perry, Ruby Swaimn, Mason Speirs, Erica Anderson,
382 Suryakala Sarilla, Amelia Dodds, Dayton Marchlewski, Timothy Williams, Afan Swan,
383 Onika Abrams, Jackson Resser, Ine Sohn, Cara Lwin, Hsi-nien (Jubilee) Tan, Stephen
384 Yeargin, James Grindstaff, Heather Prigmore, Jessica Lai, Zhouwen Liu, James D.
385 Chappell, Marcia Blair, Rendie E. McHenry, Bryan P. M. Peterson, Lauren J. Ezzell.
386 b. Columbia University: Lisa Saiman, Raul A. Silverio Francisco, Anny L. Diaz Perez, Ana M.
387 Valdez de Romero.
388 c. Stanford University: Rosita Thiessen, Marcela Lopez, Alondra A. Aguilar, Emma Stainton,
389 Grace K-Y. Tam, Jonathan Altamirano, Leanne X. Chun, Rasika Behl, Samantha A.
390 Ferguson, Yuan J. Carrington, Frank S. Zhou.
391 d. Marshfield Clinic Research Institute: Edward A. Belongia, Hannah Berger, Vicki Moon,
392 Gina Burbey, Leila Deering, Brianna Freund, Garrett Heuer, Sarah Kopitzke, Carrie
393 Marcis, Jennifer Meece, Jennifer Moran, DeeAnn Hertel, Joshua Petrie, Miriah Rotar,
394 Carla Rottscheit, Elisha Stefanski, Sandy Strey, Melissa Strupp.
395 e. University of Arizona: Ferris Alaa Ramadan, Flavia Maria Nakayima Miro, Josue Ortiz,
396 Mokenge Ndiva Mongoh.
397 f. University of North Carolina: Ayla Bullock, Amy Yang, Quenla Haehnel, Jessica Lin,
398 Julienne Reynolds, Katherine “Katie” Murray, Miriana Moreno Zivanovich, Anna
399 McShea, Brittney Figueroa, Melody Liu.
400 g. University of Colorado: Kathleen Grice, Cameron Bendalin, Sonia Chavez, Jolie Granger.
401 • We also acknowledge the households for their participation.
402 • L. Y. H. C. thanks the CDC Steven M. Teutsch Prevention Effectiveness (PE) Fellowship.

403 Data sharing statement

404 The household data are available upon reasonable request and upon completion of required approvals.
405 The R code for estimating the generation time is available at [https://github.com/CDCgov/influenza-](https://github.com/CDCgov/influenza-generation-time-us)
406 [generation-time-us](https://github.com/CDCgov/influenza-generation-time-us).

407 Disclaimer

408 The conclusions, findings, and opinions expressed by authors contributing to this article do not
409 necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public
410 Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions.

411 Declaration of Generative AI and AI-assisted technologies in the 412 writing process

413 During the preparation of this work the authors used ChatGPT in order to enhance the clarity,
414 coherence, and correctness of the writing, and to check for grammatical errors. After using this tool, the
415 authors reviewed and edited the content as needed and take full responsibility for the content of the
416 publication.

417 Declaration of interest

- 418 • M. S. S. reports a leadership role as Associate Director of the American Academy of Pediatrics'
419 Pediatric Research in Office Settings (PROS), paid to Trustees of Columbia University. All other
420 authors report no potential conflicts.
- 421 • N. M.B. reports grant/contracts from NIH to the University of North Carolina School of Medicine,
422 Doris Duke Charitable Foundation, and North Carolina Collaboratory; participation on a DSMB or
423 advisory board for the Snowball Study Technical Interchange; a leadership or fiduciary role on
424 the American Society of Tropical Medicine and Hygiene Scientific Committee; and other financial
425 or nonfinancial interests with the COVID-19 Equity Evidence Academy (RADx-UP CDCC) Steering
426 Committee and North Carolina Occupational Safety and Health Education Research Center.
- 427 • E. A. reports serving as a former consultant for Hillevax and Moderna, presenting a Merck-
428 supported lecture at the Latin American Vaccine Summit, and receipt of grant/research support
429 from Pfizer for pneumococcal pneumonia studies.
- 430 • S. R. reports grant support from BioFire.
- 431 • H. Q. N. reports grant/research support from CSL Seqirus, GSK, and ModernaTX, and honorarium
432 for participating in a consultancy group for ModernaTX outside the submitted work.
- 433 • S. H. M. reports grants/contracts from NIH, the American Academy of Pediatrics, and the Doris
434 Duke Charitable Foundation.
- 435 • E. S. reports grants or contracts to institution from Vanderbilt University Medical Center
436 (originating at CDC #75D30121C11656).
- 437 • H. K. T. has received research funding from the CDC.
- 438 • C. G. G. reports participation on an advisory board for Merck, and receipt of grant/research
439 support from AHRQ, CDC, US Food and Drug Administration, NIH, and Syneos Health.
- 440 • All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.
441 Conflicts that the editors consider relevant to the content of the manuscript have been
442 disclosed.

443 Financial support

- 444 • The parent household transmission study (the Respiratory Virus Transmission Network –
445 Sentinel) was funded by the Centers for Disease Control and Prevention (Centers for Disease
446 Control and Prevention; contracts 75D30121C11656 and 75D30121C11571) and National Center
447 for Advancing Translational Sciences (NCATS) Clinical Translational Science Award (CTSA)
448 Program, Award Number 5UL1TR002243-03.
- 449 • S. H. M. reports support to institution (Trustees of Columbia University) from Vanderbilt
450 University Medical Center (project 75D30121C11656).
- 451 • M. S. S. reports a subcontract from Vanderbilt University Medical Center (funding originated
452 from CDC) paid to Trustees of Columbia University.

453

454

455 References

- 456 Boëlle, Pierre-Yves, Séverine Ansart, Anne Cori, and Alain-Jacques Valleron. 2011. "Transmission
457 parameters of the A/H1N1 (2009) influenza virus pandemic: a review." *Influenza and Other
458 Respiratory Viruses* (Wiley Online Library) 5 (5): 306-316.
- 459 Buitrago-Garcia, Diana, Aziz Mert Ipekci, Leonie Heron, Hira Imeri, Lucia Araujo-Chaveron, Ingrid
460 Arevalo-Rodriguez, Agustín Ciapponi, et al. 2022. "Occurrence and transmission potential of
461 asymptomatic and presymptomatic SARS-CoV-2 infections: Update of a living systematic review
462 and meta-analysis." *PLOS Medicine* (Public Library of Science) 19 (5): e1003987.
- 463 Carrat, Fabrice, Elisabeta Vergu, Neil M. Ferguson, Magali Lemaitre, Simon Cauchemez, Steve Leach, and
464 Alain-Jacques Valleron. 2008. "Time Lines of Infection and Disease in Human Influenza: A Review
465 of Volunteer Challenge Studies." *American Journal of Epidemiology* (Oxford University Press) 167
466 (7): 775-785.
- 467 Cauchemez, Simon, Christl A. Donnelly, Carrie Reed, Azra C. Ghani, Christophe Fraser, Charlotte K. Kent,
468 Lyn Finelli, and Neil M. Ferguson. 2009. "Household Transmission of 2009 Pandemic Influenza A
469 (H1N1) Virus in the United States." *New England Journal of Medicine* (Mass Medical Soc) 361
470 (27): 2619-2627.
- 471 Cauchemez, Simon, Fabrice Carrat, Cecile Viboud, Alain Jacques Valleron, and Pierre-Yves Boëlle. 2004.
472 "A Bayesian MCMC approach to study transmission of influenza: application to household
473 longitudinal data." *Statistics in Medicine* (Wiley Online Library) 23 (22): 3469-3487.
- 474 Centers for Disease Control and Prevention. 2024. *Current Epidemic Growth Status (Based on Rt) for
475 States and Territories*. March 22. Accessed March 25, 2024. [https://www.cdc.gov/forecast-
476 outbreak-analytics/about/rt-estimates.html](https://www.cdc.gov/forecast-outbreak-analytics/about/rt-estimates.html).
- 477 —. 2024. *Preventing Spread of Respiratory Viruses When You're Sick*. March 1. Accessed June 11, 2024.
478 <https://www.cdc.gov/respiratory-viruses/prevention/precautions-when-sick.html>.
- 479 —. 2024. *Technical Blog: Improving CDC's Tools for Assessing Epidemic Growth*. March 5. Accessed
480 March 25, 2024. [https://www.cdc.gov/forecast-outbreak-analytics/about/technical-blog-
481 rt.html](https://www.cdc.gov/forecast-outbreak-analytics/about/technical-blog-rt.html).
- 482 Cori, A., A.J. Valleron, F. Carrat, G. Scalia Tomba, G. Thomas, and P.Y. Boëlle. 2012. "Estimating influenza
483 latency and infectious period durations using viral excretion data." *Epidemics* 4 (3): 132-138.
- 484 Cowling, Benjamin J, Vicky J Fang, Steven Riley, J S Malik Peiris, and Gabriel M Leung. 2009. "Estimation
485 of the serial interval of influenza." *Epidemiology* (LWW) 20 (3): 344--347.
- 486 Cowling, Benjamin J., Kwok Hung Chan, Vicky J. Fang, Lincoln L.H. Lau, Hau Chi So, Rita O.P. Fung,
487 Edward S.K. Ma, et al. 2010. "Comparative Epidemiology of Pandemic and Seasonal Influenza A
488 in Households." *New England Journal of Medicine* (Mass Medical Soc) 362 (23): 2175-2184.
- 489 Fraser, Christophe, Christl A. Donnelly, Simon Cauchemez, William P. Hanage, Maria D. Van Kerkhove, T.
490 Déirdre Hollingsworth, Jamie Griffin, et al. 2009. "Pandemic Potential of a Strain of Influenza A
491 (H1N1): Early Findings." *Science* (American Association for the Advancement of Science) 324
492 (5934): 1557-1561.


- 493 Gostic, Katelyn M., Lauren McGough, Edward B. Baskerville, Sam Abbott, Keya Joshi, Christine Tedijanto,
494 Rebecca Kahn, et al. 2020. "Practical considerations for measuring the effective reproductive
495 number, Rt." *PLOS Computational Biology* (Public Library of Science) 16 (12): e1008409.
- 496 Hart, William S, Elizabeth Miller, Nick J Andrews, Pauline Waight, Philip K Maini, Sebastian Funk, and
497 Robin N Thompson. 2022. "Generation time of the alpha and delta SARS-CoV-2 variants: an
498 epidemiological analysis." *The Lancet Infectious Diseases* (Elsevier) 22 (5): 603--610.
- 499 Hart, William S, Philip K Maini, and Robin N Thompson. 2021. "High infectiousness immediately before
500 COVID-19 symptom onset highlights the importance of continued contact tracing." *eLife* (eLife
501 Sciences Publications, Ltd) 10: e65534.
- 502 Hart, William S, Sam Abbott, Akira Endo, Joel Hellewell, Elizabeth Miller, Nick rews, Philip K Maini,
503 Sebastian Funk, and Robin N Thompson. 2022. "Inference of the SARS-CoV-2 generation time
504 using UK household data." *eLife* (eLife Sciences Publications, Ltd) 11: e70767.
- 505 Lau, Max S.Y., Benjamin J. Cowling, Alex R. Cook, and Steven Riley. 2015. "Inferring influenza dynamics
506 and control in households." *Proceedings of the National Academy of Sciences* (National Acad
507 Sciences) 112 (29): 9094-9099.
- 508 Lessler, Justin, Nicholas G Reich, Ron Brookmeyer, Trish M Perl, Kenrad E Nelson, and Derek AT
509 Cummings. 2009. "Incubation periods of acute respiratory viral infections: a systematic review."
510 *The Lancet infectious diseases* (Elsevier) 9 (5): 291--300.
- 511 Levy, Jens W., Benjamin J. Cowling, James M. Simmerman, Sonja J. Olsen, Vicky J. Fang, Piyarat
512 Suntarattiwong, Richard G. Jarman, Brendan Klick, and Tawee Chotipitayasonondh. 2013. "The
513 Serial Intervals of Seasonal and Pandemic Influenza Viruses in Households in Bangkok, Thailand."
514 *American Journal of Epidemiology* (Oxford University Press) 177 (12): 1443-1451.
- 515 Morris, Sinead E., Huong Q. Nguyen, Carlos G. Grijalva, Kayla E. Hanson, Yuwei Zhu, Jessica E. Biddle,
516 Jennifer K. Meece, et al. 2024. "Influenza virus shedding and symptoms: Dynamics and
517 implications from a multi-season household transmission study." *medRxiv* (Cold Spring Harbor
518 Laboratory Press) 2024--03.
- 519 Pastore, Massimiliano. 2018. "Overlapping: a R package for Estimating Overlapping in Empirical
520 Distributions." *Journal of Open Source Software* (The Open Journal) 3 (32): 1023.
- 521 Pastore, Massimiliano, and Antonio Calcagni. 2019. "Measuring Distribution Similarities Between
522 Samples: A Distribution-Free Overlapping Index." *Frontiers in Psychology* (Frontiers Media SA)
523 10: 1089.
- 524 Petrie, Joshua G., Suzanne E. Ohmit, Benjamin J. Cowling, Emileigh Johnson, Rachel T. Cross, Ryan E.
525 Malosh, Mark G. Thompson, and Arnold S. Monto. 2013. "Influenza Transmission in a Cohort of
526 Households with Children: 2010-2011." *PLOS ONE* (Public Library of Science) 8 (9): e75339.
- 527 Rolfes, Melissa A., H. Keipp Talbot, Huong Q. McLean, Melissa S. Stockwell, Katherine D. Ellingson, Karen
528 Lutrick, Natalie M. Bowman, et al. 2023. "Household Transmission of Influenza A Viruses in
529 2021-2022." *JAMA* (American Medical Association) 329 (6): 482-489.

- 530 Suess, Thorsten, Cornelius Remschmidt, Susanne B. Schink, Brunhilde Schweiger, Alla Heider, Jeanette
531 Milde, Andreas Nitsche, et al. 2012. "Comparison of Shedding Characteristics of Seasonal
532 Influenza Virus (Sub)Types and Influenza A(H1N1)pdm09; Germany, 2007–2011." *PLOS ONE*
533 (Public Library of Science) 7 (12): e51653.
- 534 Svensson, Åke. 2007. "A note on generation times in epidemic models." *Mathematical Biosciences*
535 (Elsevier) 208 (1): 300-311.
- 536 te Beest, Dennis E, Jacco Wallinga, Tjibbe Donker, and Michiel van Boven. 2013. "Estimating the
537 generation interval of influenza A (H1N1) in a range of social settings." *Epidemiology (LWW)* 24
538 (2): 244--250.
- 539 Tsang, Tim K, Lincoln LH Lau, Simon Cauchemez, and Benjamin J Cowling. 2016. "Household transmission
540 of influenza virus." *Trends in microbiology* (Elsevier) 24 (2): 123--133.
- 541 Tsang, Tim K., Can Wang, Vicky J. Fang, Ranawaka A. P. M. Perera, Hau Chi So, Dennis K. M. Ip, Gabriel
542 M. Leung, J. S. Malik Peiris, Simon Cauchemez, and Benjamin J. Cowling. 2023. "Reconstructing
543 household transmission dynamics to estimate the infectiousness of asymptomatic influenza
544 virus infections." *Proceedings of the National Academy of Sciences* 120 (33): e2304750120.
- 545 Tuite, Ashleigh R., Amy L. Greer, Michael Whelan, Anne-Luise Winter, Brenda Lee, Ping Yan, Jianhong
546 Wu, et al. 2010. "Estimated epidemiologic parameters and morbidity associated with pandemic
547 H1N1 influenza." *CMAJ* 182 (2): 131--136.
- 548 Xu, Cuiling, Kwok-Hung Chan, Tim K. Tsang, Vicky J. Fang, Rita O. P. Fung, Dennis K. M. Ip, Simon
549 Cauchemez, Gabriel M. Leung, J. S. Malik Peiris, and Benjamin J. Cowling. 2015. "Comparative
550 Epidemiology of Influenza B Yamagata- and Victoria-Lineage Viruses in Households." *American*
551 *Journal of Epidemiology* (Oxford University Press) 182 (8): 705-713.
- 552
- 553

554 **Supplementary material**

555 **The incubation period distribution**

556 The incubation period distribution was modeled using estimates for influenza A from a systematic
557 review by Lessler et al. (Lessler, et al. 2009), with a mean of 1.55 days and a standard deviation (SD) of
558 0.66 days. These estimates were fitted to a gamma distribution to characterize the distribution of the
559 incubation period (Supplemental Figure S1).



560

561 *Figure S1. Incubation period distribution. The black circles and blue lines represent the data (Lessler, et al. 2009), and the (A)*
562 *cumulative distribution function and (B) probability density function of a gamma distribution fitted to the data.*


563 **The observed household serial interval of single infection pairs**

564 We found that the observed household serial interval, calculated without modeling, solely using data
565 from households with single infection pairs (i.e., single primary case to single secondary case) and
566 without potential transmission chains, had a mean of 3.7 days (and a SD of 2.3 days). This was longer
567 than the mean intrinsic serial interval of 3.2 (95% CrI: 2.8-3.5) days when considering households of all
568 sizes with all potential transmission chains (Table 2). This does not necessarily indicate that the intrinsic
569 value was shorter than the realized household one. Rather, it is mainly due to the restriction of single
570 infection pairs or mostly smaller household sizes of 2 members.

571 In the main text, we found slightly longer mean intrinsic and realized household generation times in
572 smaller households compared to larger ones (Figure 1C and Supplemental Table S1). Larger households
573 with more exposure and potential transmission chains could have a shorter interval, while smaller
574 households could have a longer interval.

575 **Specification of parameters for the mechanistic model**

576 In the mechanistic model (Hart, Abbott, et al. 2022), two parameters, namely the ratio of the mean
577 latent and incubation period and the mean symptomatic infectious period, were estimated directly
578 (Supplemental Figure S2), while the proportion of transmission before symptomatic onset was
579 calculated by weighting the pre-symptomatic period by the ratio of pre-symptomatic and symptomatic
580 transmission rates and dividing it by the sum of the (pre-symptomatic and symptomatic) infectious
581 periods. The mean latent and mean pre-symptomatic periods were calculated by dividing the incubation
582 period by the ratio of mean latent and incubation period.



583

584 *Figure S2. Posterior and prior distributions of estimated parameters. Solid and dashed lines represent posterior and prior*
 585 *distributions, respectively.*


586 Variability in estimates across data stratifications

587 Although the generation time or serial interval of influenza B may be longer than that of influenza A
 588 (Levy, et al. 2013), this was not the case in our findings from the two seasons (Supplemental Table S1,
 589 Figure S3 and S4). However, we note that the mean intrinsic generation time exhibited a wider credible
 590 interval when using data exclusively from influenza B compared to influenza A, which likely reflects the
 591 dominance of influenza A during the study timeframe and the smaller sample size of influenza B.

Data stratifications	Mean intrinsic generation time (95% CrIs)	Overlapping index (% compared to the primary analysis)
All data excluding households with multiple co-primary cases (primary analysis in Table 1)	3.2 (2.9-3.6)	100
Season 2021/2022	3.3 (2.8-4.0)	71
Season 2022/2023	3.2 (2.8-3.6)	87
Influenza A	3.2 (2.9-3.6)	94
Influenza B	3.2 (2.3-4.5)	47


Household size of 2 or 3	3.4 (2.9-4.0)	61
Household size of 4 or greater	3.1 (2.7-3.6)	74
All data including households with multiple co-primary cases	3.1 (2.7-3.4)	64

592 *Table S1. The posterior mean (95% CrIs) of mean intrinsic generation time across seasons, virus types, household sizes, and with*
593 *multiple co-primary cases. The incubation period, derived from influenza A, had a mean of 1.55 days and a standard deviation*
594 *(SD) of 0.66 days (Lessler, et al. 2009). Only for influenza B, we assumed the shorter incubation period to yield a mean of 0.61*
595 *days and a standard deviation (SD) of 0.25 days.*



596

597 *Figure S3. Posterior distributions of parameters across data stratifications: (A) seasons, (B) virus types, (C) household sizes, and*
 598 *(D) with multiple co-primary cases.*



599

600
601

Figure S4. Posterior distributions of parameters across data stratifications: (A) seasons, (B) virus types, (C) household sizes, and (D) with multiple co-primary cases.


602 Sensitivity analyses

603 Similar to the sensitivity analyses using the full dataset, we found that the incubation period had a
604 limited effect on the intrinsic generation time when exclusively using data from households circulating
605 influenza A (Supplemental Figure S6, Panel B) or households circulating influenza B (Supplemental Figure
606 S6, Panel C).

607 Consistent with the previous study (Hart, Abbott, et al. 2022), assuming a higher relative infectiousness
608 of asymptomatic infected individuals resulted in slightly lower estimates of the overall infectiousness of
609 infectors (Supplemental Figure S6, Panel D).

Sensitivity analyses	Mean intrinsic generation time (95% CrIs)	Overlapping index (% compared to the primary analysis)
Primary analysis (in Table 1)	3.2 (2.9-3.6)	100
Longer incubation period	3.2 (2.8-3.6)	86
Shorter incubation period	3.4 (3.1-3.7)	56
Lower relative infectiousness	3.2 (2.9-3.6)	94
Higher relative infectiousness	3.2 (2.9-3.6)	97

610 *Table S2. The posterior mean (95% CrIs) of mean intrinsic generation time given different incubation periods or relative*
611 *infectiousness of asymptomatic infected individuals. The primary incubation period, derived from influenza A, had a mean of*
612 *1.55 days and a standard deviation (SD) of 0.66 days (Lessler, et al. 2009). For the shorter incubation period derived from*
613 *influenza B, we assumed a mean of 0.61 days and a SD of 0.25 days (Lessler, et al. 2009). For the longer incubation period*
614 *derived from influenza A(H1N1)pdm09, we assumed a mean of 0.61 days and a SD of 0.25 days (Tuite, et al. 2010).*



615


616

617

618

619

Figure S5. Posterior distributions of parameters given different assumptions: (A-C) incubation periods, and (D) relative infectiousness of asymptomatic infected individuals. Panel (A) presents results obtained using data from households with both influenza A and B, whereas Panels (B) and (C) present results obtained using data solely from households with influenza A and B, respectively.



620

621 *Figure S6. Posterior distributions of parameters given different assumptions: (A-C) incubation periods, and (D) relative*
 622 *infectiousness of asymptomatic infected individuals. Panel (A) presents results obtained using data from households with both*
 623 *influenza A and B, whereas Panels (B) and (C) present results obtained using data solely from households with influenza A and B,*
 624 *respectively.*